2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein - Associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 12, 2004, Pages 2302-2306

  Marsche, Gunther ^a   Heller, Regine ^b   Fauler, Günter ^a   Kovacevic, Alenka ^a   Nuszkowski, Alexander ^b   Graier, Wolfgang ^a   Sattler, Wolfgang ^a   Malle, Ernst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

2 chlorinated fatty aldehyde; Atherosclerosis; Glomerulosclerosis; Modified lipids; Myeloperoxidase; Neutrophils

Indexed keywords

2 CHLOROHEXADECANAL; ALDEHYDE; HIGH DENSITY LIPOPROTEIN; HYPOCHLOROUS ACID; NITRIC OXIDE SYNTHASE; PLASMALOGEN; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; LIPID DEGRADATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REPERFUSION INJURY;

ALDEHYDES; CELL LINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; HYPOCHLOROUS ACID; LIPOPROTEINS, HDL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; PLASMALOGENS; UMBILICAL VEINS;

EID: 10644253777     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000148703.43429.25     Document Type: Article

References (48)

1. Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood. 1998;92:3007-3017.
2. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest. 1994;94:437-444.
3. Winterbourn CC. Comparative reactivities of various biological compounds with myeloperoxidase-hydrogen peroxide-chloride, and similarity of the oxidant to hypochlorite. Biochim Biophys Acta. 1985;840:204-210.
4. Prutz WA. Hypochlorous acid interactions with thiols, nucleotides, DNA, and other biological substrates. Arch Biochem Biophys. 1996;332:110-120.
5. Hazell LJ, Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J. 1993;290:165-172.
6. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest. 1996;97:1535-1544.
7. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem. 2000;267:4495-4503.
8. Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem. 2002;277:32172-32179.
9. Malle E, Wag G, Thiery J, Sattler W, Grone HJ. Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun. 2001;289:894-900.
10. Brasen JH, Hakkinen T, Malle E, Beisiegel U, Yla-Herttuala S. Patterns of oxidized epitopes, but not NF-kappa B expression, change during atherogenesis in WHHL rabbits. Atherosclerosis. 2003;166:13-21.
11. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation. 2001;104:2376-2383.
12. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003;23:1724-1731.
13. Panzenboeck U, Raitmayer S, Reicher H, Lindner H, Glatter O, Malle E, Sattler W. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J Biol Chem. 1997;272:29711-29720.
14. Bergt C, Reicher H, Malle E, Sattler W. Hypochlorite modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages. FEBS Lett. 1999;452:295-300.
15. Pussinen PJ, Metso J, Keva R, Hirschmugl B, Sattler W, Jauhiainen M, Malle E. Plasma phospholipid transfer protein-mediated reactions are impaired by hypochlorite-modification of high density lipoprotein. Int J Biochem Cell Biol. 2003;35:192-202.
16. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-541.
17. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075-2081.
18. Vita JA, Brennan ML, Gokce N, Mann SA, Goormastic M, Shishehbor MH, Penn MS, Keaney JF Jr, Hazen SL. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110:1134-1139.
19. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992;89:10-18.
20. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ. Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem. 1999;274:32512-32519.
21. Vergnani L, Hatrik S, Ricci F, Passaro A, Manzoli N, Zuliani G, Brovkovych V, Fellin R, Malinski T. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability. Circulation. 2000;101:1261-1266.
22. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, Sawamura T. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem. 2001;276:13750-13755.
23. Chavakis E, Dernbach E, Hermann C, Mondorf UF, Zeiher AM, Dimmeler S. Oxidized LDL inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation. 2001;103:2102-2107.
24. Nuszkowski A, Gräbner R, Marsche G, Unbehaun A, Malle E, Heller R. Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem. 2001;276:14212-14221.
25. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost. 1993;70:36-41.
26. Marsche G, Zimmermann R, Horiuchi S, Tandon NN, Sattler W, Malle E. Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem. 2003;278:47562-47570.
27. Pugh EL, Kates M, Hanahan DJ. Characterization of the alkyl ether species of phosphatidylcholine in bovine heart. J Lipid Res. 1977;18:710-716.
28. 2-trimethylchlorosilane. Tetrahedron. 1992;48:4579-4586.
29. Thukkani AK, Hsu FF, Crowley JR, Wysolmerski RB, Albert CJ, Ford DA. Reactive chlorinating species produced during neutrophil activation target tissue plasmalogens: production of the chemoattractant, 2-chlorohexadecanal. J Biol Chem. 2002;277:3842-3849.
30. Albert CJ, Crowley JR, Hsu FF, Thukkani AK, Ford DA. Reactive chlorinating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens: identification of 2-chlorohexadecanal. J Biol Chem. 2001;276:23733-23741.
31. Heller R, Münscher-Paulig F, Gräbner R, Till U. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem. 1999;274:8254-8260.
32. Shaul PW, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest. 2004;113:509-513.
33. Katrantzis M, Baker MS, Handley CJ, Lowther DA. The oxidant hypochlorite (OCl-), a product of the myeloperoxidase system, degrades articular cartilage proteoglycan aggregate. Free Radic Biol Med. 1991;10:101-109.
34. Sessa WC, Garcia-Cardena G, Liu J, Keh A, Pollock JS, Bradley J, Thiru S, Braverman IM, Desai KM. The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J Biol Chem. 1995;270:17641-17644.
35. Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol. 2002;64:749-774.
36. Bergt C, Oettl K, Keller W, Andreae F, Leis HJ, Malle E, Sattler W. Reagent or myeloperoxidase-generated hypochlorite affects discrete regions in lipid-free and lipid-associated human apolipoprotein A-I. Biochem J. 2000;346:345-354.
37. Bergt C, Marsche G, Panzenboeck U, Heinecke JW, Malle E, Sattler W. Human neutrophils employ the myeloperoxidase/hydrogen peroxide/chloride system to oxidatively damage apolipoprotein A-I. Eur J Biochem. 2001;268:3523-3531.
38. Arnhold J, Osipov AN, Spalteholz H, Panasenko OM, Schiller J. Formation of lysophospholipids from unsaturated phosphatidylcholines under the influence of hypochlorous acid. Biochim Biophys Acta. 2002;1572:91-100.
39. Paltauf F. Ether lipids in biomembranes. Chem Phys Lipids. 1994;74:101-139.
40. Thukkani AK, Albert CJ, Wildsmith KR, Messner MC, Martinson BD, Hsu FF, Ford DA. Myeloperoxidase-derived reactive chlorinating species from human monocyte target plasmalogens in low density lipoprotein. J Biol Chem. 2003;278:36365-36372.
41. Thukkani AK, McHowat J, Hsu FF, Brennan ML, Hazen SL, Ford DA. Identification of α-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation. 2003;108:3128-3133.
42. Bräutigam C, Engelmann B, Reiss D, Reinhardt U, Thiery J, Richter WO, Brosche T. Plasmalogen phospholipids in plasma lipoproteins of normolipidemic donors and patients with hypercholesterolemia treated by LDL apheresis. Atherosclerosis. 1996;119:77-88.
43. Makela R, Karhunen PJ, Kunnas TA, Ilveskoski E, Kajander OA, Mikkelsson J, Perola M, Penttila A, Lehtimaki T. Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study. Lab Invest. 2003;83:919-925.
44. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce OL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142.
45. Fogelman AM. When good cholesterol goes bad. Nat Med. 2004;10:902-903.
46. Marsche O, Levak-Frank S, Quehenberger O, Heller R, Sattler W, Malle E. Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells. FASEB J. 2001;15:1095-1097.
47. Baldus S, Eiserich JP, Mani A, Castro L, Figueroa M, Chumley P, Ma W, Tousson A, White CR, Bullard DC, Brennan ML, Lusis AJ, Moore KP, Freeman BA. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001;108:1759-1770.
48. Eiserich JP, Baldus S, Brennan ML, Ma W, Zhang C, Tousson A, Castro L, Lusis AJ, Nauseef WM, White CR, Freeman BA. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391-2394.